Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Privately held Swiss firm gets $45 million upfront in deal for Phase II candidate being studied in wet age-related macular degeneration and diabetic macular edema.
Advertisement

Related Content

Deals Of The Week: Allergan/Molecular Partners, Silence Therapeutics/MiReven, Pfizer/Mylan
Allergan Inks Two More Deals With Molecular Partners On New Approach To Ophthalmic Conditions
Botox And Beyond: Allergan Lays Out Growth Strategy
Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases
Regeneron's VEGF Trap-Eye Caught In CATT's Claws
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense
Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

Topics

Advertisement
UsernamePublicRestriction

Register

PS072315

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel